Advanced lipid panel (ApoB and Lp(a))

ApoB and Lp(a) are among the best-evidenced biomarkers in the longevity-clinic universe. Both are supported by large human cohort studies and Mendelian randomisation work indicating causal, not merely correlational, contributions to atherosclerotic disease, and both are recognised in mainstream lipid guidelines. Two important honest limits apply. First, the evidence establishes them as risk markers and causal exposures, not as interventions: measuring ApoB or Lp(a) has not itself been shown in a randomised trial to extend healthspan or lifespan. Second, Lp(a) is at present largely non-actionable. It is minimally responsive to diet, exercise or statins, and the outcome data for the Lp(a)-lowering agents in late-stage development were not yet in hand at the time of writing, so a raised result mainly intensifies management of other modifiable risk factors. ApoB is more actionable, since it responds to established lipid-lowering therapy. A caveat on this record specifically: the live web-search budget for this session was exhausted before the primary literature and guideline sources could be retrieved directly, so the evidence characterisation above rests on the clinical consensus reflected in the clinical sources retrieved rather than on primary papers opened in this session. It should be re-verified against ESC/EAS and NLA guideline documents before publication.

What it is

Plain-language explainer

Categories